Roux-en-Y gastric bypass surgery is a weight loss procedure being performed for the past 20 years on individuals who are severely obese. In this procedure, new stomach pouch of a size of an egg will be created from the existing stomach to limit the amount of food intake. Obese individuals lose 30 to 40 percent of their body weight and up to 67 percent of excess body weight. But weight loss results after gastric bypass surgery vary between individuals. Some individuals unable to maintain expected weight loss. The research team led by Michelle R Lent from Geisinger Clinic, Danville, Pennsylvania found that some preoperative clinical factors predict long-term weight loss after a popular Roux-en-Y gastric bypass (RYGB) surgery. Researchers looked into medical records of 726 Roux-en-Y gastric bypass surgery patients before surgery and 7 to 12 years after surgery. The study results show
Researchers hope the found preliminary results can help healthcare professionals in predicting result after bariatric surgery. Research findings were published in the journal JAMA Surgery.
Atherosclerosis is a serious disease in which cholesterol plaque builds up inside the blood vessels. Blood vessels become narrow and harder and restricts blood flow which delivers oxygen and nutrients to organs and cells. Atherosclerosis is the usual cause for strokes, heart attacks, vascular diseases and mortality in type 2 diabetes mellitus (T2D T2DM) individuals.
Atherogenic dyslipidemia (AD) refers to a condition in individuals with small dense LDL, high levels of triglycerides (TG) and low levels of HDL cholesterol (HDL-C). In type 2 diabetes mellitus (T2D T2DM) patients, atherogenic dyslipidemia (AD) is the main contributor to the risk of lipid-related cardiovascular diseases (CVD).
During May 2015, U.S. FDA warned regarding usage of SGLT2 inhibitors as they raise the risk of diabetic ketoacidosis (DKA). They warned again during December 2015 for the same risk even if the individual is in near normal blood glucose levels. SGLT2 inhibitors are used to lower blood glucose levels and were approved for the usage by individuals with type 2 diabetes (T2D). Three drugs are available in the US under SGLT2 inhibitors category. They are
Even though they were approved for type 2 diabetes (T2D) patients, type 1 diabetes (T1D) patients can also use them. type 1 diabetes (T1D) patients face diabetic ketoacidosis (DKA) frequently while using SGLT2 inhibitors and it is important to quickly identify and treat ketoacidosis. Early diagnosis and management of ketoacidosis are important. Individuals using SGLT2 inhibitors should seek medical attention immediately if they experience symptoms such as
MiniMed 630G system with SmartGuard technology and new insulin pump is the product of Ireland based medical device company Medtronic plc. SmartGuard technology reduces incidents of low sugar. The product takes care of insulin requirements of patients with diabetes aged 16 years or more. The United States FDA recently approved the product for the commercial launch. 630G combines SmartGuard technology with a new user-friendly design which provides personalized diabetes management and advanced clinical performance.
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. Published article is not a medical advice by the OWNER of the "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.